ArticleBMC public health2025
A population-based survey of self-reported and IIEF-defined erectile dysfunction among adult men in the United States in 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults.Sexual medicine · 2026Article
- Article
- The relationship between the severity of erectile dysfunction and the risk of co-occurrence with premature ejaculation: a cross-sectional study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErectile dysfunction (ED) is the most common male sexual medical condition worldwide, but assessing its prevalence accurately is made difficult by the diversity of methodologies utilised. This study used the abridged 5-item International Index of Erectile Function (IIEF-5) questionnaire, together with estimates based on self-reported ED and ED treatments, to assess ED prevalence in the US.
methodsAnalyses were undertaken by age groups: 18-34 years; 35-49 years; 50-64 years; ≥65 years, with further assessments by socioeconomic status (SES), lifestyle and health conditions associated with ED. Continuous variables, categorical variables and multivariate logistic regression models were used.
resultsSexually active men aged ≥18 years, from all 50 USA states, Washington, DC, and Puerto Rico, were recruited through the Evidation Health, Inc. (San Mateo, CA, USA; evidation.com) health-tracking platform (n=3,289). ED prevalence was found to increase with age, from 26.0% (18-34 years) to 62.5% (≥65 years) based on the IIEF-5 questionnaire, from 19.3% to 60.0% based on ED self-perception, and from 2.6% to 29.2% based on current treatments. Other factors that were found to increase the risk of ED included low SES; health conditions, such as diabetes, chronic pain, mental health conditions; and being of Black or Asian heritage.
conclusionThis study corroborates established knowledge that ED prevalence increases with age, is strongly associated with comorbidities, and is influenced by socioeconomic factors. Importantly, our findings reveal a notable discrepancy between IIEF-5-defined ED and self-reported symptoms, highlighting a critical public health consideration: ED often serves as an early warning sign for more serious underlying health conditions. This underscores the importance of improved screening and awareness in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.